Asset
PEGVORHYALURONIDASE ALFA
Halozyme Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02563548 | phase1 | completed | 2015-10-22 | 2019-03-26 | Halozyme Therapeutics | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors |
| NCT01839487 | phase2 | completed | 2013-05-14 | 2018-05-01 | Halozyme Therapeutics | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer |
| NCT00834704 | phase1 | completed | 2009-02-01 | 2012-06-01 | Halozyme Therapeutics | Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors |
| NCT01453153 | phase1_2 | completed | 2011-09-01 | 2014-02-01 | Halozyme Therapeutics | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer |
| NCT03267940 | phase1 | terminated | 2017-10-02 | 2019-11-11 | Halozyme Therapeutics | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma |
FDA applications (0)
This company has no applications containing this asset.